College of Otolaryngology Head and Neck Surgery, National Clinical Research Center for Otolaryngologic Diseases, Key Lab of Hearing Science, Ministry of Education, Beijing Key Lab of Hearing Impairment for Prevention and Treatment, Medical School of Chinese PLA, 28 Fuxing Road, Beijing, 100853, People's Republic of China.
Department of Radiotherapy, Chinese PLA General Hospital, Beijing, 100853, People's Republic of China.
Eur Arch Otorhinolaryngol. 2022 Dec;279(12):5791-5799. doi: 10.1007/s00405-022-07446-z. Epub 2022 Aug 2.
Locally advanced nasopharyngeal carcinoma (LANC) often invades the parapharyngeal space and internal carotid artery. Are patients with LANC invading carotid artery are at risk of massive neck hemorrhage after radiotherapy?
This retrospective study included 130 LANC patients with carotid artery invasion admitted to our hospital between January 2012 and September 2019. All patients were treated with induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) ± epidermal growth factor receptor (EGFR) inhibitor. Univariate and multivariate analysis of risk factors were conducted for the prognosis and the occurrence of massive neck hemorrhage of LANC patients with carotid artery invasion.
The 5-year progression-free survival (PFS), distant metastasis-free survival (DMFS), local nodal recurrence-free survival (LNRFS), local recurrence-free survival (LRFS), nodal recurrence-free survival (NRFS) and overall survival (OS) of the 130 patients were 75.2%, 76.8%, 90.0%, 93.9%, 95.8% and 87.2%, respectively. The incidence of fatal bleeding after radiotherapy was 2.3% (3/130). The primary site of the three cases were all the pharyngeal recess, with more than 270° carotid artery invasion, suffering nasopharyngeal necrosis after radiotherapy (2 of which were diabetics and 1 received re-radiation after recurrence). Univariate analysis showed that clinical stage was negatively correlated with DMFS and PFS (P < 0.05). The induction chemotherapy TP regimen, platinum-based concurrent chemotherapy and EGFR inhibitors (Nituzumab/Cetuximab) significantly improved PFS and DMFS (P < 0.05). Patients with hemoglobin levels > 110 g/L had significantly inferior PFS, DMFS and OS than those with hemoglobin levels ≤ 110 g/L (P < 0.05). Multivariate analysis showed that the EGFR inhibitor was an independent risk factor for PFS and DMFS, while the lowest hemoglobin level was an independent risk factor for OS.
In LANC patients whose carotid artery invasion was < 270°, induction chemotherapy (IC) followed by helical tomotherapy (HT) and concurrent chemoradiotherapy (CCRT) with EGFR (epidermal growth factor receptor) inhibitor had mild and tolerable side effects, better PFS and DMFS, with no massive hemorrhage. In patients whose primary tumor was pharyngeal recess with carotid artery invasion ≥ 270°, poorly controlled diabetes or re-radiotherapy led to a higher risk of massive hemorrhage after radiotherapy.
局部晚期鼻咽癌(LANC)常侵犯咽旁间隙和颈内动脉。颈内动脉受侵犯的 LANC 患者在放疗后是否有发生大出血的风险?
本回顾性研究纳入了 2012 年 1 月至 2019 年 9 月期间我院收治的 130 例颈内动脉受侵犯的 LANC 患者。所有患者均接受诱导化疗联合同期放化疗(CCRT)±表皮生长因子受体(EGFR)抑制剂治疗。对颈内动脉受侵犯的 LANC 患者的预后和大出血发生情况进行单因素和多因素分析。
130 例患者的 5 年无进展生存(PFS)、无远处转移生存(DMFS)、局部淋巴结无复发生存(LNRFS)、局部无复发生存(LRFS)、无淋巴结转移生存(NRFS)和总生存(OS)分别为 75.2%、76.8%、90.0%、93.9%、95.8%和 87.2%。放疗后致命性出血的发生率为 2.3%(3/130)。3 例患者的原发部位均为咽隐窝,颈内动脉受侵犯超过 270°,放疗后发生鼻咽坏死(其中 2 例为糖尿病患者,1 例为复发后再次放疗)。单因素分析显示,临床分期与 DMFS 和 PFS 呈负相关(P<0.05)。诱导化疗 TP 方案、含铂同期化疗和 EGFR 抑制剂(尼妥珠单抗/西妥昔单抗)显著改善了 PFS 和 DMFS(P<0.05)。血红蛋白水平>110 g/L 的患者 PFS、DMFS 和 OS 明显低于血红蛋白水平≤110 g/L 的患者(P<0.05)。多因素分析显示,EGFR 抑制剂是 PFS 和 DMFS 的独立危险因素,而最低血红蛋白水平是 OS 的独立危险因素。
对于颈内动脉受侵犯<270°的 LANC 患者,采用诱导化疗(IC)联合螺旋断层放疗(HT)和含 EGFR(表皮生长因子受体)抑制剂的同期放化疗,具有轻度、可耐受的副作用,可获得更好的 PFS 和 DMFS,且无大出血发生。对于原发肿瘤位于咽隐窝、颈内动脉受侵犯≥270°、糖尿病控制不佳或再次放疗的患者,放疗后发生大出血的风险较高。